Mark Mal­lon charts post-Iron­wood course by tak­ing CEO job at NeoGe­nomics; Glax­o­SmithK­line vet Feng Ren joins In­sil­i­co as CSO

Mark Mal­lon steps aside at Iron­wood on March 12 af­ter close to two years at the helm, and he al­ready has a new change of scenery squared away. Be­gin­ning April 19, Mal­lon takes charge as CEO of can­cer-fo­cused ge­net­ic test mak­er NeoGe­nomics out of Fort My­ers, FL while his pre­de­ces­sor, Dou­glas VanOort, is re­tir­ing af­ter 12 years as NeoGe­nomics’ chair­man and CEO.

It’s a fresh start for Mal­lon af­ter what will amount to a tu­mul­tuous 23 months as Iron­wood’s chief ex­ec­u­tive. Last year was marked by tri­al fail­ures that spelled dou­ble trou­ble, leav­ing the Iron­wood cup­board bare: first, a Linzess re­for­mu­la­tion for ir­ri­ta­ble bow­el syn­drome with di­ar­rhea (IBS-D) in May, and then the drug IW-3718 for per­sis­tent acid re­flux in Sep­tem­ber. Af­ter IW-3718’s dis­con­tin­u­a­tion, Iron­wood chopped its staff by 35%. On Feb. 8, Mal­lon an­nounced his de­par­ture at Iron­wood, with pres­i­dent Tom Mc­Court get­ting bumped up to in­ter­im CEO.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.